Interpace Diagnostics Group (NASDAQ:IDXG) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, ValuEngine reports.

Other analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Interpace Diagnostics Group in a report on Thursday, November 14th. Maxim Group set a $2.00 price objective on shares of Interpace Diagnostics Group and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Oppenheimer initiated coverage on shares of Interpace Diagnostics Group in a report on Thursday, September 26th. They set an “outperform” rating and a $3.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Interpace Diagnostics Group currently has an average rating of “Buy” and an average price target of $2.33.

IDXG stock opened at $0.45 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.57. Interpace Diagnostics Group has a twelve month low of $0.38 and a twelve month high of $1.15. The company’s 50 day moving average is $0.70 and its two-hundred day moving average is $0.75. The stock has a market cap of $18.34 million, a P/E ratio of -1.05 and a beta of 2.18.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings data on Wednesday, November 13th. The business services provider reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). Interpace Diagnostics Group had a negative net margin of 77.55% and a negative return on equity of 58.48%. The company had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $10.00 million. On average, equities research analysts predict that Interpace Diagnostics Group will post -0.44 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in IDXG. River & Mercantile Asset Management LLP purchased a new position in shares of Interpace Diagnostics Group during the second quarter worth approximately $468,000. Perkins Capital Management Inc. grew its position in shares of Interpace Diagnostics Group by 22.5% during the third quarter. Perkins Capital Management Inc. now owns 2,360,385 shares of the business services provider’s stock worth $1,876,000 after acquiring an additional 433,135 shares during the last quarter. Stonepine Capital Management LLC grew its position in shares of Interpace Diagnostics Group by 22.3% during the second quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock worth $1,271,000 after acquiring an additional 319,154 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its position in shares of Interpace Diagnostics Group by 98.0% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock worth $32,000 after acquiring an additional 22,150 shares during the last quarter. Institutional investors and hedge funds own 18.74% of the company’s stock.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Further Reading: Forex

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.